These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24737877)

  • 1. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
    [No Abstract]   [Full Text] [Related]  

  • 3. PhRMA sues on 340B orphans.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
    [No Abstract]   [Full Text] [Related]  

  • 4. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Reach of the 340B Drug Pricing Program.
    Albrecht J; Mudahar S
    JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
    [No Abstract]   [Full Text] [Related]  

  • 6. Rx: higher prices.
    Kosterlitz J
    Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare and drug pricing.
    Iglehart JK
    N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
    [No Abstract]   [Full Text] [Related]  

  • 8. CMS retreats on Part D rule intended to reduce drug costs and improve access.
    Dickson V
    Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
    [No Abstract]   [Full Text] [Related]  

  • 9. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 11. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 12. Opinion: price controls on prescription drugs.
    Franks B
    N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel approaches to delivering value in oncology drugs.
    Miller S
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 15. Creating a medical home through the 340B Drug Pricing Program.
    Genao I; Hendrickson K; Diers D; Browne R; Rawlings JE
    Conn Med; 2010; 74(10):615-20. PubMed ID: 21189719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. States sue generic drug makers for alleged price fixing.
    McCarthy M
    BMJ; 2016 Dec; 355():i6764. PubMed ID: 27993771
    [No Abstract]   [Full Text] [Related]  

  • 17. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 18. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 19. Keynote comment: Cancer drug pricing in the USA.
    Johnson DH
    Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.